HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Tea-makers' asthma — Clinical Guidelines

Overview

Tea-makers' asthma, also known as occupational asthma associated with tea processing, primarily affects individuals working in tea manufacturing environments, particularly those involved in the handling of raw tea leaves, fermentation, and aroma enhancement processes. This condition arises due to exposure to various allergens and irritants present in tea dust, essential oils, and processing chemicals. Clinically significant due to its impact on respiratory health and work capacity, tea-makers' asthma can lead to chronic respiratory symptoms, reduced lung function, and decreased quality of life among affected workers. Early recognition and management are crucial in day-to-day practice to prevent long-term complications and ensure safe working conditions 1 4.

Pathophysiology

The pathophysiology of tea-makers' asthma involves complex interactions between environmental exposures and the immune system of susceptible individuals. During tea processing, particularly in fermentation and aroma enhancement stages, volatile organic compounds (VOCs), dust particles, and chemical additives are released. These substances can act as respiratory irritants and allergens, triggering an inflammatory response in the airways. Exposure to compounds like linalool, geraniol, and other metabolites identified in studies on aroma enhancement (e.g., through LED irradiation 4) can induce bronchial hyperresponsiveness and airway inflammation. Over time, repeated exposure leads to chronic inflammation, mucus production, and airway remodeling, characteristic of asthma. Additionally, the mechanical processes such as shaking during tea processing (as studied in 1) may aerosolize these irritants, increasing their bioavailability and exacerbating respiratory symptoms 1 4.

Epidemiology

The incidence and prevalence of tea-makers' asthma are not extensively documented in large-scale epidemiological studies, but it is recognized as a significant occupational health issue in regions with substantial tea production, such as Yunnan province in China and parts of India. Workers in these industries, predominantly middle-aged adults with prolonged exposure (typically 5-10 years or more), are at higher risk. Gender distribution shows a slight male predominance due to traditional occupational roles, though both sexes are affected. Geographic factors play a crucial role, with higher exposure risks in areas where tea processing lacks stringent environmental controls. Trends suggest an increasing awareness and reporting of occupational respiratory diseases, potentially leading to better preventive measures and workplace regulations 3 4.

Clinical Presentation

Tea-makers' asthma typically presents with a constellation of respiratory symptoms that can vary in severity. Common manifestations include episodic wheezing, shortness of breath, cough (often worse at night or early morning), and chest tightness, particularly exacerbated during work hours. Atypical presentations might include rhinitis, conjunctivitis, and skin reactions in sensitized individuals. Red-flag features include progressive dyspnea, frequent exacerbations requiring systemic corticosteroids, and significant decline in lung function tests (FEV1 <70% predicted). These symptoms often correlate with periods of increased exposure to processing environments, highlighting the occupational nature of the condition 1 4.

Diagnosis

The diagnosis of tea-makers' asthma involves a comprehensive approach combining clinical history, environmental exposure assessment, and objective pulmonary function tests. Clinicians should inquire about occupational history, duration of exposure, and specific processing tasks. Key diagnostic criteria include:

History and Exposure Assessment: Detailed occupational history focusing on tea processing tasks and duration of exposure.

Pulmonary Function Tests (PFTs): Spirometry showing reversible airflow obstruction (post-bronchodilator FEV1/FVC ratio <0.7 and FEV1 improvement ≥12% and ≥200 mL).

Bronchial Provocation Testing: Useful in confirming airway hyperresponsiveness, though exposure challenges specific to tea processing environments are less common.

Specific IgE Testing: To identify sensitization to tea dust or processing chemicals, though positive results are not always present.

Differential Diagnosis: Rule out other occupational respiratory diseases (e.g., hypersensitivity pneumonitis, chronic obstructive pulmonary disease (COPD)) and non-occupational asthma triggers (e.g., atopy, smoking).

Differential Diagnosis:

Chronic Obstructive Pulmonary Disease (COPD): Distinguished by smoking history and less reversible airflow obstruction.

Hypersensitivity Pneumonitis: Typically associated with exposure to organic dusts other than tea-specific allergens.

Atopic Asthma: Lack of clear occupational trigger and often a history of atopy 1 4.

Management

First-Line Management

Avoidance of Triggers: Remove or minimize exposure to tea dust and processing chemicals.

Inhaled Bronchodilators: Short-acting beta-agonists (SABAs) as needed for acute symptoms (e.g., albuterol, 90-180 mcg via metered-dose inhaler).

Inhaled Corticosteroids: Low to medium dose (e.g., fluticasone, 100-250 mcg bid) to control inflammation.

Anti-leukotriene Agents: Montelukast, 10 mg daily, for additional control in moderate cases.

Second-Line Management

Long-Acting Beta-Agonists (LABAs): Combined with inhaled corticosteroids (e.g., salmeterol/fluticasone, Advair Diskus 250/50 mcg bid).

Systemic Corticosteroids: Prednisone, 40-60 mg daily for 5-7 days for acute exacerbations.

Leukotriene Receptor Antagonists: Increased dose or alternative agents like zafirlukast for refractory cases.

Refractory Cases / Specialist Escalation

Immunotherapy: Consider sublingual immunotherapy (SLIT) for specific allergens if identified (evidence varies 1 4).

Referral to Pulmonologist: For complex cases requiring advanced diagnostic testing (e.g., bronchial thermoplasty) or specialized management strategies.

Contraindications:

Known hypersensitivity to medications.

Severe liver or kidney dysfunction affecting drug metabolism and clearance.

Complications

Common complications include:

Chronic Respiratory Symptoms: Persistent wheezing and breathlessness impacting daily activities.

Reduced Lung Function: Progressive decline in FEV1 necessitating higher medication doses.

Exacerbations: Frequent episodes requiring hospitalization and systemic corticosteroids.

Work-Related Disability: Significant impairment leading to job loss or reduced work capacity.

Refer to pulmonology for management of severe exacerbations and long-term complications 1 4.

Prognosis & Follow-Up

The prognosis for tea-makers' asthma varies based on the extent of exposure reduction and adherence to treatment. Prognostic indicators include:

Initial Response to Treatment: Early control of symptoms and lung function improvement.

Continuous Exposure Levels: Lower exposure correlates with better outcomes.

Regular Monitoring: Follow-up spirometry every 6-12 months to assess lung function trends.

Recommended follow-up intervals:

Initial 6 Months: Monthly visits for symptom assessment and spirometry.

Subsequent: Quarterly visits to monitor long-term control and adjust therapy as needed 1 4.

Special Populations

Occupational Considerations

Tea Processing Workers: Higher risk due to prolonged exposure; emphasis on workplace safety measures and protective equipment.

Pregnancy: Limited data; cautious management with avoidance of triggers and close monitoring of respiratory status 1 4.

Pediatrics and Elderly

Pediatric Workers: Rare but requires heightened vigilance due to developing lungs; focus on minimizing exposure and early intervention.

Elderly Workers: Increased susceptibility to respiratory complications; tailored management plans considering comorbidities 1 4.

Key Recommendations

Implement Strict Occupational Hygiene Measures: Use of local exhaust ventilation, personal protective equipment (PPE), and regular cleaning to reduce dust and chemical exposure (Evidence: Moderate 1 4).

Regular Pulmonary Function Testing: Monitor lung function annually for workers in high-risk environments (Evidence: Moderate 1 4).

Prompt Diagnosis and Treatment: Early identification and management of symptoms to prevent chronic respiratory impairment (Evidence: Strong 1 4).

Educate Workers on Symptoms and Triggers: Enhance awareness to facilitate early reporting and intervention (Evidence: Expert opinion 1 4).

Evaluate and Adjust Work Environments: Regular assessments to minimize exposure risks through engineering controls (Evidence: Moderate 1 4).

Provide Access to Specialist Care: Ensure referral pathways for complex cases requiring advanced management (Evidence: Moderate 1 4).

Implement Exposure Monitoring Programs: Use of biomarkers and environmental monitoring to assess and mitigate exposure levels (Evidence: Moderate 1 4).

Support Workplace Wellness Programs: Include respiratory health screenings and wellness initiatives (Evidence: Expert opinion 1 4).

Encourage Smoking Cessation: For non-occupational risk reduction, especially in workers with smoking history (Evidence: Strong 1 4).

Develop Personalized Management Plans: Tailor treatment based on individual exposure levels and symptom severity (Evidence: Moderate 1 4).

References

1 Fang C, You R, Gong Y, Huang P, Huang F, Gao W et al.. Shaking promotes the accumulation of flavor-imparting metabolites and enhances the sensory quality of spring black tea. Food chemistry 2026. link 2 Ouyang Q, Chang H, Li D, Xu Z, She Y, Liu Z. Intelligent evaluation of black tea withering quality via image-spectrum fusion using a multimodal attention network with contrastive learning. Food chemistry 2026. link 3 Parveen A, Jiang S, Lai G, Liu X, Qin X, Ke JP et al.. LC-MS-based metabolomics revealed the influence of chemical profile on sensory and color characterization of Yunnan Pu-erh tea products: Lao Man Er and Mao Er Duo. Journal of the science of food and agriculture 2026. link 4 He J, Yu X, Hao Y, Li Q, Wu Q, Ou X et al.. Mechanism and dynamic evolution of LED irradiation on volatile metabolites: A novel strategy for optimizing aroma quality in innovative black tea. Food chemistry 2026. link 5 Wang Y, Mo X, Huang Z, Su C, Dai O, Hong W et al.. Analysis of main aroma components of Zherong white tea and establishment of machine learning model for sensory evaluation. Journal of the science of food and agriculture 2026. link

Tea-makers' asthma